« Previous
Next »
Fertility and Sterility
Volume 91, Issue 5
, Pages 1654-1656
, May 2009
Return to fertility after cessation of a continuous oral contraceptive
References
- . Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142–1149
- . Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261–266
- . Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception. 2006;74:439–445
- . The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception. 1974;10:181–202
- . Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand. Lancet. 1980;1:509–512
- . Conception delay after oral contraceptive use: the effect of estrogen dose. Fertil Steril. 1990;53:21–27
- . Is previous use of hormonal contraception associated with a detrimental effect on subsequent fecundity?. Hum Reprod. 2004;19:344–351
- . Comprehensive gynecology. 4th ed.. St. Louis: Mosby; 2001;
- . Rapid resumption of ovulation and menstruation following continuous use of the combination oral contraceptive. [abstract] Fertil Steril. 2005;83:S16
- . Prolonged use of oral contraception before a planned pregnancy is associated with a decreased risk of delayed conception. Hum Reprod. 2002;10:2754–2761
- . Fertility after discontinuation of treatment with an oral contraceptive containing 30 μg of ethinyl estradiol and 2 mg of dienogest. Fertil Steril. 2006;85:1812–1819
- . Delay in conception for former 'pill' users. JAMA. 1982;247:629–632
- . The occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. Fertil Steril. 2008;89:1059–1063
Supported by a grant from Wyeth Research, Collegeville, Pa.
K.B. was an investigator for this poststudy follow-up and received research funding from Wyeth Research, Collegeville, Pa. Other sources of research funding and/or financial relationships include Novo Nordisk (consultant), Organon (speaker and investigator), Johnson & Johnson, Duramed, Xanodyne, Boehringer Ingelheim, Third Wave, Pfizer, and MGI Pharma (investigator). S.M., G.G., and G.C. are employees of Wyeth Research. Other financial affiliation for G.G. is Johnson & Johnson. S.M. and G.C. have no other financial affiliation to disclose.
PII: S0015-0282(08)00484-6
doi: 10.1016/j.fertnstert.2008.02.122
© 2009 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Fertility and Sterility
Volume 91, Issue 5
, Pages 1654-1656
, May 2009

